Hepatitis Monthly

Published by: Kowsar

Heterogeneity and New Epitopes of Hepatitis C Virus Genotype 4

Moataza H. Omran 1 , * , Wael Nabil 1 , Samar S. Youssef 1 , Mervat El-Sayed 2 and Mostafa K. El Awady 1
Authors Information
1 Microbial Biotechnology Department, Genetic Engineering Division, National Research Centre, Dokki Cairo, Egypt
2 Chemistry Department, Faculty of Science, Cairo University, Dokki Cairo, Egypt
Article information
  • Hepatitis Monthly: July 01, 2013, 13 (8); e10521
  • Published Online: July 30, 2013
  • Article Type: Research Article
  • Received: January 31, 2013
  • Revised: April 14, 2013
  • Accepted: June 20, 2013
  • DOI: 10.5812/hepatmon.10521

To Cite: Omran M H, Nabil W, Youssef S S, El-Sayed M, El Awady M K. Heterogeneity and New Epitopes of Hepatitis C Virus Genotype 4, Hepat Mon. 2013 ; 13(8):e10521. doi: 10.5812/hepatmon.10521.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussions
  • 1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-9[DOI][PubMed]
  • 2. Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol. 2007; 88: 1526-31[DOI][PubMed]
  • 3. Simmonds P, Liang TJ, Jay HH. Biomedical Research Reports. 2000; : 53-70
  • 4. Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama. 2001; 55(3): 133-59[PubMed]
  • 5. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13(2): 223-35[PubMed]
  • 6. Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Research. 2001; 52(2): 153-9[DOI]
  • 7. El-Awady M, Youssef S, Omran M, Tabll A, El Garf W, Salem A. Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection. BMC Infect Dis. 2006; 6(1): 1-7[DOI]
  • 8. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35(1): 201-7[PubMed]
  • 9. Notices. Cladistics. 1989; 5(2): 163-6[DOI]
  • 10. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol. 2002; 76(17): 8757-68[PubMed]
  • 11. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis. 2000; 20(1): 103-26[PubMed]
  • 12. Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol. 2007; 13(36): 4808-17[PubMed]
  • 13. Quer J, Murillo P, Martell M, Gomez J, Esteban JI, Esteban R, et al. Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J Viral Hepat. 2004; 11(1): 45-54[PubMed]
  • 14. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007; 13(17): 2416-26[PubMed]
  • 15. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One. 2008; 3(5)[DOI][PubMed]
  • 16. Omran MH, Youssef SS, El-Garf WT, Tabll AA, Bader-Eldin NG, Atef K, et al. Phylogenetic and Genotyping of Hepatitis C Virus in Egypt. Australia J Basic Appl Sci. 2009; 3(1): 1-8
  • 17. Malta Fde M, Medeiros-Filho JE, Azevedo RS, Goncalves L, Silva LC, Carrilho FJ, et al. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis. Mem Inst Oswaldo Cruz. 2010; 105(1): 92-8[PubMed]
  • 18. von Messling V, Cattaneo R. N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion. J Virol. 2003; 77(19): 10202-12[PubMed]
  • 19. Al-Qahtani AA, Rubino S, Al-Ahdal MN. Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-alpha and ribavirin treatment. J Infect Dev Ctries. 2011; 5(5): 370-6[PubMed]
  • 20. Goffard A, Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie. 2003; 85(3–4): 295-301[DOI]
  • 21. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol. 2007; 81(15): 8101-11[DOI][PubMed]
  • 22. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol. 2005; 79(13): 8400-9[DOI][PubMed]
  • 23. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006; 6(3): 231-43[DOI][PubMed]
  • 24. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005; 102(26): 9294-9[DOI][PubMed]
  • 25. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol. 2005; 43(4): 1902-9[DOI][PubMed]
  • 26. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol. 2005; 79(17): 11095-104[DOI][PubMed]
  • 27. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A. 2007; 104(20): 8449-54[DOI][PubMed]
  • 28. Lavillette D, Pecheur EI, Donot P, Fresquet J, Molle J, Corbau R, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol. 2007; 81(16): 8752-65[DOI][PubMed]
  • 29. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A. 2004; 101(19): 7270-4[DOI]
  • 30. Thomson M, Liang TJ, Liang TJ, Jay HH. Biomedical Research Reports. 2000; : 1
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments